The 5th Digital Pharma Europe conference

25 - 27 February 2013, Bristol-Myers Squibb HQ, Paris, France.
Digital Pharma Europe is one of the key component conferences of the ground breaking Digital Pharma Series. ExL Pharma has leveraged the global network of industry experts to further analyze global industry perceptions and pain points and match these with interactive and practical solutions. Through our conversations with ePatients, doctors and healthcare organizations, pharma marketers, brand/product managers, agencies and technology providers, the message is clear: The most sought after tool in better equipping marketing teams and progressing digital marketing strategy is the opportunity for peer-to-peer contact to enable groundbreaking technical and strategy roll out.

The 5th Digital Pharma Europe conference not only leverages the largest platform of pharmaceutical marketing expertise from our global directory of contacts to provide these deliverables, but the agenda is specifically structured to meet the varying needs and requirements for practitioners working across the breadth of brand marketing and technical support functions in European organizations.

The challenges and innovations within the digital, social media and mobile marketing space continue to develop at pace and attendees at Digital Pharma Europe can expect to benchmark, learn from and interact with senior level professionals covering the multitude of topics concerning pharma marketing business today. The below topics will be covered in a practical perspective allowing for takeaway and delivery back in the office:

  • ePatient and Doctor/Physician network's evolution and the innovative tools for their interaction with pharma: Profiling interaction of newer social media channels such as Tweet chats and video calls on Google+, and the strategies used to deliver messages to doctors
  • Examining technologies developed to communicate B2B with stakeholders
  • Discussing how to effectively monitor and manage off-label discussions, and how you can deal with open platforms for patients from a technical and regulatory oversight standpoint
  • Social listening - listening to professional and patient conversations: Organizational strategy for leveraging feedback received from consumers and physicians from multiple channels
  • Gamification and how to actually impact upon patient behavior and compliance
  • The advent on non-pharma based organizations providing preventative mobile health solutions and the impact on pharma business
  • Physician App development without pharma marketing input: The why's and how's?
  • Big Data: transitioning with handling small to big data, carefully handling patient privacy without incurring regulatory pressure
  • Building highly effective and revenue generating digital marketing teams from the ground up: examination of digital and social media marketing training and how to build digital marketing specialists from a traditional marketing background
  • Change management and transitioning your strategy to incorporate social media and digital mediums to effect behavioral responses
  • App as medical devices: understanding at what point an App transitions from being an information sharing resource to a data usable medical device. Aligning the regulatory requirements with business development and effectiveness for your sales operations
  • Multi-Channel Marketing: analyzing whether pharma marketing will become MCM at a base level in future
  • Examining how to effectively measure the ROI of MCM and covey this to senior management: what to look for, metrics, suites of tools and identification of the alterations/channels that result in a change of behavior
  • How to operate with a multimedia mix - how can pharma work with the full range, not just social media etc

Digital Pharma Europe is the only industry event that continues to be hosted by a leading pharmaceutical company. This year it will be at Bristol Myers-Squibb HQ in Paris, France.

For further information and registration, please visit:
http://www.digitalpharmaseries.com/europe/

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara┬« (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...